Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 9
Submit an article Journal homepage
59
Views
1
CrossRef citations to date
0
Altmetric
Review

Potassium channel blockers as immunosuppressants

Jonathan B Baell The Walter and Eliza Hall Institute of Medical Research, Biotechnology Centre, 4 Research Avenue, La Trobe R & D Park, Bundoora 3086, Australia. [email protected]
Pages 1209-1220 | Published online: 02 Dec 2005

Bibliography

  • GOLDHILL J, HIGGS G: Rheumatoid arthritis: emerging drug discovery targets and therapeutic candidates. A Lead Discovery Report. (October 2003). See (201).
  • WICKENDEN AD: K* channels as therapeutic drug targets. Pharmacol Therap. (2002) 94:157–182.
  • COGHLAN MJ, CARROLL WA, GOPALAKRISHNAN M: Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J. Med. Chem. (2001) 44:1627–1653.
  • CHANDY KG, CAHALAN M, PENNINGTON M et al.: Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon (2001) 39:1269–1276.
  • CHANDY KG, WULFF H, BEETON C et al.: K* channels as targets for specific immunomodulation. Trends PharmacoL Sci. (2004) 25:280–289.
  • WULFF H, BEETON C, CHANDY KG: Potassium channels as therapeutic targets for autoimmune disorders. Cuff. Opin. Drug Discov. Dev. (2003) 6:640–647.
  • DECOURSEY TE, CHANDY KG, GUPTA SC et al.: Voltage-gated IQ channels in human T lymphocytes: a role in mitogenesis? Nature (1984) 307:465–468.
  • MATTESON DR, DEUTSCH C: K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature (1984) 307:468–471.
  • CAHALAN MD, CHANDY KG, DECOURSEY TE et al.: A voltage-gated potassium channel in human T lymphocytes. J. Physiol. (1985) 358:197–237.
  • SCHLICHTER L, SIDELL N, HAGIWARA S: IQ- channels are expressed early in human T-cell development. Proc. Natl Acad. Sci. USA (1986) 83:5625–5629.
  • WULFF H, CALABRESI P, ALLIE R et al.: The voltage-gated Kv1.3 IQ- channel in effector memory T cells as new target for MS. J. Clin. Invest. (2003) 111:1703–1713.
  • WULFF H, KNAUS H, PENNINGTON M et al :IQ channel expression during B cell differentiation: implications for immunodulation and autoimmunity. J. Immunol (2004) 173:776–786.
  • SALLUSTO F, LENIG D, FORSTER R et al.: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 401:708–712.
  • RUS H, PARDO CA, HU L et al.: The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl Acad. Sci. USA (25 July 2005) 10.1073/pnas.0501770102 (online).
  • CORCIONE A, CASAZZA S, FERRITTI E et al. : Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Nail Acad. Sci. USA (2004) 101:11064–11069.
  • BEETON C, WULFF H, BARBARIA J et al.: Selective blockade of T lymphocyte IQ- channels amelioriates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl Acad. Sci. USA (2001) 98:13942–13947.
  • BEETON C, PENNINGTON MW, WULFF H et al.: Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. MoL PharmacoL (2005) 67:1369–1381.
  • BAO J, MIAO S, KAYSER F et al: Potent Kv1.3 inhibitors from correolide - modification of the C18 position. Bioorg. Med. Chem. Lett. (2005) 15:447–451.
  • MIAO M, BAO J, GARCIA ML et al.: Benzamide derivatives as blockers of the Kv1.3 ion channel. Bioorg. Med. Chem. Lett. (2003) 13:1161–1164.
  • SCHMALHOFER WA, BAO J, MCMANUS OB et al.: Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochem. (2002) 41:7781–7794.
  • SCHMALHOFER WA, SLAUGHTER RS, MATYSKIELA M et al.: Di-substituted cyclohexyl derivatives bind to two identical sites with postive cooperativity on the voltage-gated potassium channel, Kv1.3. Biochem. (2003) 42:4733–4743.
  • BAELL JB, GABLE RW, HARVEY AJ et al.: Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J. Med. Chem. (2004) 47:2326–2336.
  • VENNEKAMP J, WULFF H, BEETON C et al: Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. MoL PharmacoL (2004) 65:1364–1374.
  • SANKARANARAYANAN A, SCHMITZ A, SCHMIDT-LASSEN K et al.: Design of a selective small molecule Kv1.3 blocker. 229th ACS Meeting. San Diego, USA (2005). MEDI107.
  • HAHLBROCK K, ZILG H, GRISEBACH H: Stereochemistry of the enzymatic cyclisation of 4,2',4'-trihydroxychalcone to 7,4'-dihydroxyflavanone by isomerases from mung bean seedlings. Eur. j Biochem. (1970) 15:13–18.
  • JEZ J, BOWMAN ME, DIXON RA et al.: Structure and mechanism of the evolutionarily unique plant enzyme chalcone isomerase. Nat. Struct. Biol. (2000) 7:786–791.
  • CHEN MX, GORMAN SA, BENSON B et al.: Small and intermediate conductance Ca2*- activated IQ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. Naunyn Schmiedebergs Arch. Pharmacol (2004) 369:602–615
  • BOETTGER MK, TILLS, CHEN MX et al.: Calcium-activated potassium channel SK1- and IK1- like immunoreactivity in injured human sensory neurones and its regulation by neurotrophic factors. Brain (2002) 125:252–263
  • FURNESS JB, ROBBINS HL, SELMER I-Set al. : Expression of intermediate conductance potassium channel immunoreactivity in neurons and epithelial cells of the rat gastrointestinal tract. Cell Tissue Res. (2003) 314:179–189
  • JOINER WJ, BASAVAPPA S, VIDYASAGAR S et al.: Active K* secretion occurs through multiple types of KCa channels and is regulated by IKCa channels in rat proximal colon. Am. J. PhysioL (2003) 285:G185–G196
  • URBAHNS K, HORVATH E, STASCH J-P et al.: 4-Phenyl-4H-pyrans as IKCa channel blockers. Bioorg Med. Chem. Lett. (2003) 13:2637–2639.
  • URBAHNS K, GOLDMANN S, KRUEGER Jet al.: IKCa-channel blockers. Part 2: Discovery of cyclohexadienes. Bioorg. Med. Chem. Lett. (2005) 15:401–404.
  • WERMUTH CG: Selective optimization of side activities: another way for drug discovery. J. Med. Chem. (2004) 47:1303–1314.
  • WULFF H, MILLER MJ, HAENSEL W et al.: Design of a potent and selective inhibitor of the intermediate-conductance Ca2*-activated IQ channel, KCa3.1: a potential immunosuppressant. Proc. Nail. Acad. Sci. USA (2000) 97:8151–8156.
  • STOCKER JW, DE FRANCESCHI L, MCNAUGHTON-SMITH GA et aL: ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood (2003) 101:2412–2418.
  • KOEHLER R, WULFF H, EICHLER I et al.: Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 108:1119–1125.
  • GRGIC I, EICHLER I, HEINAU P et al.: Selective blockade of the intermediate-conductance Ca2* -activated K* channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. (2005) 25:704–709.
  • REICH: EP, CUI L, YANG L et al.: Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur. J. ImmunoL (2005) 35:1027–1036.
  • XU J, WANG P, LI Yet al.: The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc. Nail. Acad. Sci. USA (2004) 101:3112–3117.
  • XU J, KONI PA, WANG P et aL: The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Hum. MoL Genet. (2003) 12:551–559.
  • DORNER T, LIPSKY PE: Correlation of circulating CD27 high plasma cells and disease activity in systemic lupus erythematosus. Lupus (2004) 13:283–289.
  • BEETON C, CHANDY KG: Potassium channels, memory T cells and multiple sclerosis. Neuroscientist (in press).
  • FADOOL DA, TUCKER K, PERKINS R et al.: Kv1.3 Channel gene-targeted deletion produces 'super-smeller mice' with altered glomeruli, interacting scaffolding proteins, and biophysics. Neuron (2004) 41:389–404.

Websites

  • http://www.leaddiscovery.co.uk/reports/ rheumatoid°/020arthritis.html

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.